I read so much about a "partnership" to continue BoM2.  With a partner funding BoM2 the profits most likely will be divided by 50/50 and testing extended for years.  Seems the patents are running short of time.  In the end RVX would only see 50% of ABL value, big dilution in share price.

What was said earlier in this forum, the Breakthrough label is worth about 8B in value.  Just that value represents $32 per share with 250 M shares to split profits.  So where does the $5 per share come from.  Damaged goods?   Please add all the benefits of ABL, all.  There is substantial value.

Now, why the silent treatment from BP?  Burned once, Burned twice, do not know or they are all waiting to pick the pieces cheap.  Shareholder value -0-.

It really is time to find buyer, just to keep life in Don’s baby.  The perfect storm hit RVX, just missing P3, COVID, Lack of Funds, No Revenue and the great spin to Zeneith.  It all points to finding a buyer to keep ABL moving to approval for the benefit of all.  How does RVX stay afloat with no revenue and having a partner run BOM2?  Future partner should just buy RVX and take 100% of profits and all the formulas on the shelf.

This is all MHO.  Sidebar.